Abstract The existence of effective therapies for most cardiovascular disease states. coupled with increased requirements that potential benefits of new drugs be evaluated on clinical rather than surrogate endpoints. makes it increasingly difficult to substantiate any incremental improvements in efficacy that these new drugs might offer. Compounding the problem is the highly controver... https://www.truvisionhealthftp.com/